Literature DB >> 28888422

Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks.

Ryusuke Murakami1, Noriomi Matsumura2, J B Brown3, Koichiro Higasa4, Takanobu Tsutsumi4, Mayumi Kamada5, Hisham Abou-Taleb1, Yuko Hosoe1, Sachiko Kitamura1, Ken Yamaguchi1, Kaoru Abiko1, Junzo Hamanishi1, Tsukasa Baba1, Masafumi Koshiyama1, Yasushi Okuno5, Ryo Yamada4, Fumihiko Matsuda4, Ikuo Konishi1, Masaki Mandai6.   

Abstract

Previous studies have reported genome-wide mutation profile analyses in ovarian clear cell carcinomas (OCCCs). This study aims to identify specific novel molecular alterations by combined analyses of somatic mutation and copy number variation. We performed whole exome sequencing of 39 OCCC samples with 16 matching blood tissue samples. Four hundred twenty-six genes had recurrent somatic mutations. Among the 39 samples, ARID1A (62%) and PIK3CA (51%) were frequently mutated, as were genes such as KRAS (10%), PPP2R1A (10%), and PTEN (5%), that have been reported in previous OCCC studies. We also detected mutations in MLL3 (15%), ARID1B (10%), and PIK3R1 (8%), which are associations not previously reported. Gene interaction analysis and functional assessment revealed that mutated genes were clustered into groups pertaining to chromatin remodeling, cell proliferation, DNA repair and cell cycle checkpointing, and cytoskeletal organization. Copy number variation analysis identified frequent amplification in chr8q (64%), chr20q (54%), and chr17q (46%) loci as well as deletion in chr19p (41%), chr13q (28%), chr9q (21%), and chr18q (21%) loci. Integration of the analyses uncovered that frequently mutated or amplified/deleted genes were involved in the KRAS/phosphatidylinositol 3-kinase (82%) and MYC/retinoblastoma (75%) pathways as well as the critical chromatin remodeling complex switch/sucrose nonfermentable (85%). The individual and integrated analyses contribute details about the OCCC genomic landscape, which could lead to enhanced diagnostics and therapeutic options.
Copyright © 2017 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28888422     DOI: 10.1016/j.ajpath.2017.06.012

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  Active learning effectively identifies a minimal set of maximally informative and asymptotically performant cytotoxic structure-activity patterns in NCI-60 cell lines.

Authors:  Takumi Nakano; Shunichi Takeda; J B Brown
Journal:  RSC Med Chem       Date:  2020-07-20

Review 2.  Precision medicine for ovarian clear cell carcinoma based on gene alterations.

Authors:  Takafumi Kuroda; Takashi Kohno
Journal:  Int J Clin Oncol       Date:  2020-02-04       Impact factor: 3.402

Review 3.  Epithelial Mutations in Endometriosis: Link to Ovarian Cancer.

Authors:  Serdar E Bulun; Yong Wan; Daniela Matei
Journal:  Endocrinology       Date:  2019-03-01       Impact factor: 4.736

4.  Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers.

Authors:  Joseph A Zundell; Takeshi Fukumoto; Jianhuang Lin; Nail Fatkhudinov; Timothy Nacarelli; Andrew V Kossenkov; Qin Liu; Joel Cassel; Chih-Chi Andrew Hu; Shuai Wu; Rugang Zhang
Journal:  Cancer Res       Date:  2021-09-21       Impact factor: 13.312

Review 5.  Ovarian teratoid carcinosarcoma with a PIK3CA mutation: a case report and review of the literature.

Authors:  Masato Aoki; Hisamitsu Takaya; Tomoyuki Otani; Hidekatsu Nakai; Kosuke Murakami; Noriomi Matsumura
Journal:  Int Cancer Conf J       Date:  2022-08-08

Review 6.  Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Authors:  Ugo Testa; Eleonora Petrucci; Luca Pasquini; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2018-02-01

7.  Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma.

Authors:  Shuai Wu; Takeshi Fukumoto; Jianhuang Lin; Timothy Nacarelli; Yemin Wang; Dionzie Ong; Heng Liu; Nail Fatkhutdinov; Joseph A Zundell; Sergey Karakashev; Wei Zhou; Lauren E Schwartz; Hsin-Yao Tang; Ronny Drapkin; Qin Liu; David G Huntsman; Andrew V Kossenkov; David W Speicher; Zachary T Schug; Chi Van Dang; Rugang Zhang
Journal:  Nat Cancer       Date:  2021-01-11

Review 8.  ARID1 proteins: from transcriptional and post-translational regulation to carcinogenesis and potential therapeutics.

Authors:  Olena Odnokoz; Cindy Wavelet-Vermuse; Shelby L Hophan; Serdar Bulun; Yong Wan
Journal:  Epigenomics       Date:  2021-04-23       Impact factor: 4.778

9.  Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.

Authors:  Takeshi Fukumoto; Pyoung Hwa Park; Shuai Wu; Nail Fatkhutdinov; Sergey Karakashev; Timothy Nacarelli; Andrew V Kossenkov; David W Speicher; Stephanie Jean; Lin Zhang; Tian-Li Wang; Ie-Ming Shih; Jose R Conejo-Garcia; Benjamin G Bitler; Rugang Zhang
Journal:  Cell Rep       Date:  2018-03-27       Impact factor: 9.423

Review 10.  Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms.

Authors:  Seiichi Mori; Osamu Gotoh; Kazuma Kiyotani; Siew Kee Low
Journal:  J Hum Genet       Date:  2021-06-07       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.